AST 1753
Alternative Names: AST-1753Latest Information Update: 05 Oct 2021
At a glance
- Originator IHM-Labs
- Developer IHM-Labs; NC-Bio; Wayne State University
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
- Discontinued Bacterial endocarditis; Tuberculosis
Most Recent Events
- 05 Oct 2021 No development reported - Phase-III for Methicillin-resistant Staphylococcus aureus infections (PO)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (PO, Capsule)
- 11 May 2018 Discontinued - Preclinical for Tuberculosis in Russia (PO)